tbuckley/cabot-search huggingface dataset:
Non-Age-Related Neoplastic Loss of Sex Chromosomecorrelated to Prolonged Survival in CBF-AML Patients in Real-World Clinical Setting
Authors: Akio Mori, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Toru Miyajima, Emi Yokoyama, Reiki Ogasawara, Koh Izumiyama, Makoto Saito, Fujisawa Shinichi, Shuichi Ota, Yasutaka Kakinoki, Yutaka Tsutsumi, Satoshi Yamamoto, Takuto Miyagishima, Takahiro Nagashima, Hiroshi Iwasaki, Hajime Kobayashi, Yoshihito Haseyama, Mitsutoshi Kurosawa, Masanobu Morioka, Takanori Teshima, Takeshi Kondo
Journal: Blood (2021)
Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors
Authors: Fadi Haddad, Hagop Kantarjian, Elias J. Jabbour, Nicholas J. Short, Naveen Pemmaraju, Kayleigh Marx, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa
Journal: Blood (2021)
Association of Social Support With Functional Outcomes in Older Adults Who Live Alone
Authors: Sachin J. Shah, Margaret C. Fang, S. Rae Wannier, Michael A. Steinman, Kenneth E. Covinsky
Journal: JAMA Internal Medicine (2021)

<h3>Importance</h3> Older adults who live alone are at risk for poor health outcomes. Whether social support mitigates the risk of living alone, particularly when facing a sudden change in health, has not been adequately reported. <h3>Objective</h3> To assess if identifiable support buffers the vulnerability of a health shock while living alone. <h3>Design, Setting, and Participants</h3> In this longitudinal, prospective, nationally representative cohort study from the Health and Retirement Study (enrollment March 2006 to April 2015), 4772 community-dwelling older adults 65 years or older who lived alone in the community and could complete activities of daily living (ADLs) and instrumental ADLs independently were followed up biennially through April 2018. Statistical analysis was completed from May 2020 to March 2021. <h3>Exposures</h3> Identifiable support (ie, can the participant identify a relative/friend who could help with personal care if needed), health shock (ie, hospitalization, new diagnosis of cancer, stroke, heart attack), and interaction (multiplicative and additive) between the 2 exposures. <h3>Main Outcomes and Measures</h3> The primary outcomes were incident ADL dependency, prolonged nursing home stay (≥30 days), and death. <h3>Results</h3> Of 4772 older adults (median [IQR] age, 73 [68-81] years; 3398 [71%] women) who lived alone, at baseline, 1813 (38%) could not identify support, and 3013 (63%) experienced a health shock during the study. Support was associated with a lower risk of a prolonged nursing home stay at 2 years (predicted probability, 6.7% vs 5.2%;<i>P</i> = .002). Absent a health shock, support was not associated with a prolonged nursing home stay (predicted probability over 2 years, 1.9% vs 1.4%;<i>P</i> = .21). However, in the presence of a health shock, support was associated with a lower risk of a prolonged nursing home stay (predicted probability over 2 years, 14.2% vs 10.9%;<i>P</i> = .002). Support was not associated with incident ADL dependence or death. <h3>Conclusions and Relevance</h3> In this longitudinal cohort study among older adults who live alone, identifiable support was associated with a lower risk of a prolonged nursing home stay in the setting of a health shock.
Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database
Authors: Gregory S Calip, Mustafa S Ascha, Xiaoliang Wang, Amy E Pierre, Kathleen Maignan, Niquelle B Wadé, Siyang Leng, Erlene K Seymour, Brian C-H Chiu, Karen Sweiss, Pritesh R Patel, Natalia Neparidze
Journal: Blood (2021)
Abstract 9393: A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease
Authors: Siddharth M Patel, Nicholas A Marston, Giorgio E Melloni, Frederick K Kamanu, Carolina Roselli, Elliott M Antman, Deepak L Bhatt, Eugene Braunwald, Christopher P Cannon, Michelle L Odonoghue, Robert P Giugliano, Ofri Mosenzon, Benjamin M Scirica, Steven A Lubitz, Patrick T Ellinor, Marc P Bonaca, Marc S Sabatine, Christian T Ruff
Journal: Circulation (2021)

Introduction: GWAS have identified SNPs associated with an increased risk of peripheral artery disease (PAD). We sought to compare the performance of a genetic risk score (GRS) comprised of these SNPs with established clinical risk factors to predict PAD and acute limb ischemia (ALI) across five RCTs in cardiometabolic disease. Given high prevalence of coronary artery disease (CAD) in patients with PAD, we also evaluated the performance of the GRS for incident myocardial infarction (MI). Methods: Pts from the ENGAGE AF-TIMI 48, SOLID-TIMI 52, SAVOR-TIMI 53, PEGASUS-TIMI 54, and FOURIER trials were included in this analysis. ALI and MI were adjudicated by a blinded CEC comprised of vascular medicine specialists and cardiologists. A previously validated GRS ( Nature Medicine 2019) of 19 SNPs associated with PAD was calculated for each pt. ORs for PAD were calculated across genetic risk groups. HRs adjusted for clinical risk factors were calculated for ALI and incident MI. Results: Of 51,729 total pts included in this analysis, 5,149 (10%) had PAD at baseline. Pts in the top 20% of GRS had 47% higher odds of having PAD compared with those in the bottom 20% (adj OR 1.47, 95% CI 1.33-1.62; p&lt;0.001). The magnitude of risk for PAD conferred by high GRS was similar to many established clinical risk factors (Figure). A total of 91 ALI events occurred over a median follow-up of 2.4 years. Pts in the top 20% of GRS were at 63% increased risk for ALI compared with those in the bottom 80% (adj HR 1.63, 95% CI 1.04-2.56.; p=0.03), consistent in those with and without PAD (p-interaction 0.85). The PAD GRS was also associated with incident MI (n=2323), with pts in the top 20% of GRS at 42% increased risk compared with the bottom 80% (adj HR 1.42, 95% CI 1.36-1.49; p&lt;0.001). Conclusions: A 19-SNP GRS was a strong independent predictor of PAD and ALI in patients with cardiometabolic disease. The PAD GRS also predicted MI, supporting overlapping biological mechanisms for atherosclerosis across vascular beds.
Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents
Authors: Song Cai, Aubin Moutal, Jie Yu, Lindsey A. Chew, Jörg Isensee, Reena Chawla, Kimberly Gomez, Shizhen Luo, Yuan Zhou, Aude Chefdeville, Cynthia Madura, Samantha Perez-Miller, Shreya Sai Bellampalli, Angie Dorame, David D. Scott, Liberty François-Moutal, Zhiming Shan, Taylor Woodward, Vijay Gokhale, Andrea G. Hohmann, Todd W. Vanderah, Marcel Patek, May Khanna, Tim Hucho, Rajesh Khanna
Journal: Science Translational Medicine (2021)

Protein-protein interaction inhibitor of the sodium NaV1.7 channel has analgesic effects in preclinical models of pain.
CD38 Is a Key Regulator of Tumor Growth By Modulating the Metabolic Signature of Malignant Plasma Cells
Authors: Ruxandra Maria Irimia, Margo Brooke Gerke, Maya Thakar, Zhihong Ren, Eric Helmenstine, Philip H. Imus, Gabriel Ghiaur, Robert Leone, Christian B. Gocke
Journal: Blood (2021)
Dysfunctional <i>HDAC8</i> Impacts Genomic Integrity and Is a Novel Therapeutic Target in Multiple Myeloma
Authors: Zuzana Chyra, Srikanth Talluri, Rao Prabhala, Mehmet K. Samur, Anil Aktas-Samur, Yan Xu, Aaron B. Beeler, Roman Hajek, Mariateresa Fulciniti, Masood A. Shammas, Nikhil C. Munshi
Journal: Blood (2021)
Measuring diagnostic performance of COVID-19 tests: lessons for the next pandemic
Authors: Jacob Moran-Gilad
Journal: Eurosurveillance (2021)

Preview this article: Measuring diagnostic performance of COVID-19 tests: lessons for the next pandemic, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/26/45/eurosurv-26-45-1-1.gif
Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study
Authors: Yunju Ma, Changju Qu, Haiping Dai, Sining Liu, Qingya Cui, Wei Cui, Jia Yin, Liqing Kang, Xiaying Lian, Huiying Qiu, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Journal: Blood (2021)
Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments
Authors: Jordan E. Krull, Kerstin Wenzl, Michelle K. Manske, Melissa A. Hopper, Melissa C. Larson, Vivekananda Sarangi, Matthew J. Maurer, Zhi-Zhang Yang, Lisa M. Rimsza, Brian K. Link, Thomas M. Habermann, Stephen M. Ansell, Rebecca L. King, James R. Cerhan, Anne J. Novak
Journal: Blood (2021)
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
Authors: Jorge E. Cortes, Jordi Esteve, Ashish Bajel, Karen Yee, Thorsten Braun, Stephane De Botton, Pierre Peterlin, Christian Recher, Xavier Thomas, Justin Watts, Montserrat Arnan Sangerman, Antonio Curti, Carolyn Grove, Brian A. Jonas, Francesco Lanza, Olivier Legrand, Pau Montesinos, Prapti Patel, Thomas Prebet, Eunice S. Wang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Pierre Fenaux, Andrew H. Wei
Journal: Blood (2021)
Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of <i>SF3B1</i> Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes
Authors: Federico Gaiti, Allegra Hawkins, Paulina Chamely, Ariel Swett, Xiaoguang Dai, Lloyd Kluegel, Celine Chen, John Beaulaurier, Alex Drong, Scott Hickey, Tarek H Mouhieddine, Franco Izzo, Neville Dusaj, Ronan Chaligne, Sissel Juul, Daniel H Wiseman, Eoghan Harrington, Justin Taylor, Irene M. Ghobrial, Omar Abdel-Wahab, Dan A. Landau
Journal: Blood (2021)
Abstract 9212: Smartwatch-Based 6 Minutes Walking Distance Measurement in Pulmonary Hypertension Patients: A Pilot Study
Authors: Weihao Li, Jiajun Guo, Lili Wang, Yucheng Chen
Journal: Circulation (2021)

Introduction: The 6 minutes walking test (6MWT) is a simple and practical measurement of exercise capacity with minimal cost. In pulmonary hypertension (PH), 6MWT results indicates severity of disease and risk of adverse events, thus working as a main end point for clinical trials. Conventionally, 6MWTs are conducted by health care professionals. Hypothesis: Smartwatch might help to conduct 6MWT and measure walking distances. Methods: Patients with PH on routine follow-up visits and asymptomatic volunteers were enrolled in this study. Every studied subjects was required to wear a smartwatch (HUAWEI Watch GT2) on each wrist before walking on a 50-meter long, flat and straight path. The 6 minutes’ walk was under the supervision of two trained doctors, with dedicated research application and vibration of smartwatches as a reminder of start and stop. No encouragement were used during walk. Walking distances measured by the doctors were recorded. Distances measured by smartwatches were retrieved from HUAWEI Research platform. Results: A total of 45 patients with pulmonary hypertension (aged 40.0±11.8) and 21 asymptomatic volunteers (aged 24.2±1.25) participated this study. 6MWTs were successful for all participants, with 2 PH patients prematurely stopped walking due to mild dizziness. Smartwatches gave valid measurements of distances for all tests. Walking distances measured by doctors and by smartwatches showed good consistency. (No statistically significant differences, p=0.794; Intraclass correlation coefficient 0.9782(0.9630 to 0.9870) for left wrist, 0.9568(0.9276 to 0.9742) for right wrist). And the difference between left and right wrist measurements were minimal (paired t tests: 8.73±6.07 m, CI: -3.42-20.88, p=0.156). Conclusions: Smartwatch-based 6MWT measurements were feasible in PH patients and volunteers. Although further calibration may be needed, it’s promising for future management of PH and other cardiopulmonary diseases.
Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series
Authors: Jacqueline N. Poston, Kadhim Al-Banaa, Annette von Drygalski, Aric D. Parnes, Christopher E Walsh, James F Wu, Craig M. Kessler, Maissaa Janbain, Lynn M Malec, Rebecca Kruse-Jarres
Journal: Blood (2021)
Abstract PO-031: Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA
Authors: Dilru Silva, Conan Kinsey, Martin McMahon
Journal: Cancer Research (2021)

Abstract The current FDA-approved chemotherapies for patients with Pancreatic Ductal Adenocarcinoma (PDA) demonstrate substantial toxicities with only a modest survival benefit highlighting the urgent need to better understand the molecular mechanisms driving PDA and how they interact in order to develop more precise and less toxic pathway-targeted therapies. PDA often harbors oncogenic mutations in KRAS and CDKN2A that drive a dysregulated cell cycle through activation of CDK4/6 (Cyclin-Dependent Kinases 4 and 6), which mono-phosphorylate RB1 to govern progression through G0◊G1◊S phases. Currently, there are three FDA-approved CDK4/6 inhibitors, palbo-, abema-, and ribociclib (X-ciclibs), that are predicted to have anti-cancer activity in PDA cells. However, the benefits of X-ciclib treatment in PDA patients are largely underwhelming. We found that inherent resistance to X-ciclib treatment in vitro is due to compensatory activation of protective autophagy, a critical lysosomal degradation process that generates a source of nutrients during periods of cellular stress. We observed that X-ciclib treatment induces autophagic flux in PDA cell lines. This pro-cancer process can be targeted with the lysosomal inhibitors, chloroquine and hydroxychloroquine. The addition of chloroquine sensitizes PDA cells to X-ciclib treatment, resulting in diminished proliferative ability. Additionally, a late-stage PDA patient was treated with the combination of an X-ciclib and hydroxychloroquine and displayed a dramatic decrease in the bloodborne PDA biomarker, Cancer Antigen 19-9. These data may suggest a novel combination treatment strategy for late-stage PDA patients, but the molecular mechanisms underlying are yet to be studied in PDA. Future work will explore the role RB1 plays in CDK4/6 regulated autophagy by investigating how phosphorylation at distinct RB1 sites modulates autophagy-related gene expression and the extent to which mTORC1 deactivation is necessary for CDK4/6 regulated autophagy. Citation Format: Dilru Silva, Conan Kinsey, Martin McMahon. Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-031.
Reporting guidelines for human microbiome research: the STORMS checklist
Authors: Chloe Mirzayi, Audrey Renson, Cesare Furlanello, Susanna-Assunta Sansone, Fatima Zohra, Shaimaa Elsafoury, Ludwig Geistlinger, Lora J. Kasselman, Kelly Eckenrode, Janneke van de Wijgert, Amy Loughman, Francine Z. Marques, David A. MacIntyre, Manimozhiyan Arumugam, Rimsha Azhar, Francesco Beghini, Kirk Bergstrom, Ami Bhatt, Jordan E. Bisanz, Jonathan Braun, Hector Corrada Bravo, Gregory A. Buck, Frederic Bushman, David Casero, Gerard Clarke, Maria Carmen Collado, Paul D. Cotter, John F. Cryan, Ryan T. Demmer, Suzanne Devkota, Eran Elinav, Juan S. Escobar, Jennifer Fettweis, Robert D. Finn, Anthony A. Fodor, Sofia Forslund, Andre Franke, Cesare Furlanello, Jack Gilbert, Elizabeth Grice, Benjamin Haibe-Kains, Scott Handley, Pamela Herd, Susan Holmes, Jonathan P. Jacobs, Lisa Karstens, Rob Knight, Dan Knights, Omry Koren, Douglas S. Kwon, Morgan Langille, Brianna Lindsay, Dermot McGovern, Alice C. McHardy, Shannon McWeeney, Noel T. Mueller, Luigi Nezi, Matthew Olm, Noah Palm, Edoardo Pasolli, Jeroen Raes, Matthew R. Redinbo, Malte Rühlemann, R. Balfour Sartor, Patrick D. Schloss, Lynn Schriml, Eran Segal, Michelle Shardell, Thomas Sharpton, Ekaterina Smirnova, Harry Sokol, Justin L. Sonnenburg, Sujatha Srinivasan, Louise B. Thingholm, Peter J. Turnbaugh, Vaibhav Upadhyay, Ramona L. Walls, Paul Wilmes, Takuji Yamada, Georg Zeller, Mingyu Zhang, Ni Zhao, Liping Zhao, Wenjun Bao, Aedin Culhane, Viswanath Devanarayan, Joaquin Dopazo, Xiaohui Fan, Matthias Fischer, Wendell Jones, Rebecca Kusko, Christopher E. Mason, Tim R. Mercer, Susanna-Assunta Sansone, Andreas Scherer, Leming Shi, Shraddha Thakkar, Weida Tong, Russ Wolfinger, Christopher Hunter, Nicola Segata, Curtis Huttenhower, Jennifer B. Dowd, Heidi E. Jones, Levi Waldron
Journal: Nature Medicine (2021)

The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for observational or genetic epidemiology studies lack key features specific to microbiome studies. Therefore, a multidisciplinary group of microbiome epidemiology researchers adapted guidelines for observational and genetic studies to culture-independent human microbiome studies, and also developed new reporting elements for laboratory, bioinformatics and statistical analyses tailored to microbiome studies. The resulting tool, called 'Strengthening The Organization and Reporting of Microbiome Studies' (STORMS), is composed of a 17-item checklist organized into six sections that correspond to the typical sections of a scientific publication, presented as an editable table for inclusion in supplementary materials. The STORMS checklist provides guidance for concise and complete reporting of microbiome studies that will facilitate manuscript preparation, peer review, and reader comprehension of publications and comparative analysis of published results.
Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome
Authors: Alessandra Magnani, Michaela Semeraro, Frédéric ADAM, Claire Booth, Loic Dupre, Emma C Morris, Aurélie Gabrion, Cecile Roudaut, Delphine Borgel, Antoine Toubert, Emmanuel Clave, Chrystelle Abdo, Guy Gorochov, Rachel Petermann, Mélanie Guiot, Makoto Miyara, Despina Moshous, Elisa Magrin, Adeline Denis, Felipe Suarez, Chantal Lagresle-Peyrou, Aoife Doto, John K. Everett, Amélie Trinquand, Marianne Guisset, Jin Hua Xu-Bayford, Salima Hacein-Bey-Abina, Alexandre Kauskot, Reem Elfeky, Christine Rivat, Sarah Abbas, Bobby H Gaspar, Elizabeth A. Macintyre, Capucine Picard, Frederic D. Bushman, Anne Galy, Alain Fischer, Emmanuelle Six, Adrian J. Thrasher, Marina Cavazzana
Journal: Blood (2021)
Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study
Authors: Feng Wang, Boris Gorsh, Maral DerSarkissian, Prani Paka, Rachel Bhak, Natalie Boytsov, Miriam L. Zichlin, Leah Sansbury, Christopher W. Yee, Shannon Ferrante, Anamika Khanal, Ahmed Noman, Mei Sheng Duh
Journal: Blood (2021)
Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)
Authors: Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades
Journal: Blood (2021)
Abstract 13085: Accelerated Aging is Associated With Cardiometabolic, Hematologic and Renal Abnormalities: A Project Baseline Health Substudy
Authors: Best Uchehara, Lydia Kwee, Jessica A Regan, Ranee Montgomery, Julie Eckstrand, Susan Swope, Garry Gold, Terry Schaack, Francois Haddad, Joy Wu, Scarlet Shore, Jessica Mega, Robert Califf, Adrian F Hernandez, Kenneth Mahaffey, Neha J Pagidipati, Svati H Shah
Journal: Circulation (2021)

Background: Genetic methylation patterns correlate with age, but some individuals demonstrate accelerated biologic aging as determined by higher methylation/epigenetic age compared with actual chronologic age. Objective: To determine characteristics of individuals who have accelerated aging (AA). Methods: The Project Baseline Health (PBH) study recruited 2501 participants who underwent multiple assessments (imaging, functional assessments, biospecimens) at enrollment and had annual visits. Methylation profiling (Illumina EPIC) was performed on enrollment blood samples (N=1661); repeat profiling was performed on year 1 blood (N=260). The Horvath method was used to calculate biologic age from methylation data. AA was calculated as the residual of the difference between methylation (i.e. biologic) and chronologic age. Characteristics were compared between low and high AA groups using linear and logistic regression. Results: Of 1661 individuals, 195 were low AA (-14.9 to -5.0 yrs difference in biologic vs chronologic age) and 188 were high AA (5.0 - 17.3 yrs). Discriminating characteristics between high and low AA were sex (60% vs 39% male), uric acid, BMI and waist circumference (all p&lt;0.001, all higher in high AA), and hypertension (37% vs. 27%, p&lt;0.05). Other laboratory variables that were significantly higher in the high AA group included: triglycerides, multiple complete blood count indices, creatinine and ALT (all p&lt;0.05). Lab variables lower in high AA included: HDL cholesterol, 25-OH vitamin D, and glomerular filtration rate (all p&lt;0.05). In a subset (N=260) with repeat methylation, individuals with biologic aging greater than chronologic aging had higher baseline glucose and diastolic blood pressure (p&lt;0.05), and a trend for lower vitamin D (p=0.06). Conclusions: In this Project Baseline Health study, we used deep phenotyping to identify abnormalities associated with accelerated aging. Individuals with high AA had up to a 15 year higher biologic vs. chronologic age and were more often male with greater cardiometabolic, hematologic and renal abnormalities, and lower vitamin D levels. These results highlight factors that may mediate adverse effects of aging and identify targets for mitigation of these effects in future studies.
춘계학술대회 : 포스터전시 ; 이소성 간에 생긴 간세포암: 1예 보고
Authors: 김경아, 박철민, 이창희, 최재웅, 연종은, 변관수, 이창홍
Journal: Clinical and Molecular Hepatology (2005)

배경/목적: 이소성 간세포암이란 간외 장기나 조직에 위치하는 간실질에서 발생한 간세포암으로 정의할 수 있다. 이소성 간에서 기원하는 간세포암의 발생빈도는 매우 낮으며, 1965년부터 1999년까지 23예만이 보고되었을 뿐이다. 저자들은 CT 스캔에서 비장 종괴처럼 보였던 이소성 간에서 생긴 간세포암의 드문 증례를 보고하고자한다. 수술 7개월후 추적검사 CT 스캔에서는 모 (mother) 간에 다발성 간세포암을 보였다. 국제적 문헌에 이소성 간에 생긴 간
Vitamin C Enhances PARPi Efficacy for the Treatment of AML
Authors: John P Brabson, Tiffany Leesang, Byron Fang, Jingjing Wang, Victoria Strippoli, Yoon-Sing Yap, Sofia Mohammad, Carolina Bañuelos, Peter Lyon, Sana Chaudhry, Minh Lam, Benjamin G Neel, Stephen Nimer, Ramiro E Verdun, Daniel Bilbao, Maria E. Figueroa, Luisa Cimmino
Journal: Blood (2021)
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)
Authors: Francesca Palandri, Nicola Vianelli, David M Ross, Tara Cochrane, Steven W Lane, Stephen R Larsen, Aaron T. Gerds, Anna B. Halpern, Jake Shortt, James M. Rossetti, Kristen M. Pettit, Amber Jones, Jennifer Peppe, Georges Natsoulis, Willis Navarro, Wan-Jen Hong, William S. Stevenson, Claire N. Harrison, Moshe Talpaz, Hugh Young Rienhoff
Journal: Blood (2021)